Jul. 28 at 11:11 AM
Oppenheimer🏁
$WVE Outperform/
$24.
$KRRO $ALNY $BEAM $ARWR VRTX SNY KMDA
Oppenheimer said in its research report: "We initiate Wave Life Sciences (
$WVE) with an Outperform rating and a
$24 price target.
We view
$WVE as a leading innovator in advancing RNA medicine enabled by the proprietary PRISM platform, with four clinical-stage programs showing
emerging differentiated profiles.
We are particularly optimistic about WVE-006/-007, representing first-in-class programs, as we await additional catalysts from both programs in 2H25.
Following the proof-of-mechanism update of WVE-006 in AATD last year, we see a favorable risk/reward setup heading into additional updates in 2H at the current share price level. Furthermore, initial clinical data for WVE-007 in obesity could unlock significant potential with differentiated target and modality.
We think RNA medicine represents an appealing modality for various indications, with potential to transform medical practice from treatment to prevention."
